Zusammenfassung
Damit eine adjuvante Behandlung irgendwelcher Art nach Lokalbehandlung eines malignen Tumors in Erwagung gezogen werden kann, müssen zwei grundsätzliche Voraussetzungen erfüllt sein:
-
1.
Notorisch ungünstiger natürlicher Verlauf bei allen Patienten mit diesem Tumor oder in bestimmten, klar erkennbaren Risikogruppen, bzw. wahrscheinliche rasche Rezidive und/oder Fermetastasen ohne Zusatzbehandlung.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Preview
Unable to display preview. Download preview PDF.
Literatur
Bast, R. C. et al., BCG and Cancer. New Engl. J. Med. 290, 1413–1420 und 1458–1469 (1974)
Blume, M. R. et al., Comparison of BCG with transfer factor in adjuvant immunotherapy of stage III malignant melanoma. Proc. ASCO C-241 (1977)
Bluming, A. Z., Immunological effects of BCG in malignant melanoma: two modes of administration compared. Ann. intern. med. 76, 405–411 (1972)
Borberg, H., Die BCG-Behandlung des malignen Melanoms. Internist 16, 483–485 (1975)
Bukowski, R. M. et al., The Transfer Factor therapy of stage II malignant melanoma. In „Adjuvant therapy of cancer<<, Amsterdam: Elsevier North Holland Pubi. p. 431–438. 1976
Cassel, W. A., Viral oncolysate in the management of malignant melanoma. Cancer 40, 672–679 und 680–686 (1977)
Clark, W. H., The developmental biology of primary human malignant melanomas. Semin. Oncol. 2, 83–103 (1975)
Comis, R. L., DTIC in malignant melanoma: a perspective. Cancer Treat. Rep. 60, 165–176 (1976)
Currie, G. A., Cancer and the immune response. London: Edward Arnold 1974
Currie, G. A., et al., Active Immunotherapy as an adjunct to chemotherapy in the treatment of disseminated malignant melanoma: a pilot study. Br. J. Cancer 31, 143–156 (1977)
DeVita, V. T., Fisher R. I., Natural history of malignant melanoma as related to therapy. Cancer Treat. Rep. 60, 153–157 (1976)
Dilawari, R. A. et al., Treatment of primary melanoma with intralesional BCG. Proc. ASCO 1191 (1975)
Eilber, F. R. et al., Adjuvant immunotherapy with BCG in treatment of regional-lymphnode metastases from malignant melanoma. New Engl. J. Med. 294, 237–240 (1976)
Eilber, F. R. et al., Results of BCG adjuvant immunotherapy for melanoma of the head and neck. Amer. J. Surg. 132, 476–479 (1976)
Einhorn, L. H. et al., Chemotherapy of disseminated malignant melanoma. Cancer Res. 34, 1995–2004 (1974)
EI-Domeiri, A. A. et al., Adjuvant therapy of melanoma. Proc. AACR, 709 (1977)
Elwood, J. M., Lee J. A. H., Recent data on the epidemiology of malignant melanoma. Semin. Oncol. 2, 83–103 (1975)
Everall, J. D. et al., Treatment of primary melanoma with intralesional BCG before excision. Lancet 2, 583–586 (1975)
Everall J. D., Diagnosis, prognosis and treatment of melanoma. Lancet 2, 286–289 (1977)
Florentin, I., Experimental basis of BCC systemic immunotherapy. Cancer Immunol. Immunother. 1, 7–9 (1976)
Grant, R. M., Results of administering BCG to patients with melanoma. Lancet 2, 1096–1100 (1974)
Grooms, G. A., Morton D. L., Failure of adjuvant immunotherapy to prevent brain metastases in malignant melanoma. Proc. ASCO 1160 (1975)
Gutterman, J. U. et al., Active immunotherapy with BCG for recurrent malignant melanoma. Lancet 1, 1208–1212 (1973)
Gutterman, J. U. et al., Chemoimmunotherapy of disseminated malignant melanoma with DTIC and BCG. New Engl. J. Med. 291, 592–597 (1974)
Gutterman, J. U. et al., BCG Immunotherapy in combination with DTIC for the treatment of malignant melanoma. Cancer Treat. Rep. 60, 177–182 (1976)
Gutterman, J. U. et al., An effective new chemo-immunotherapy regimen for disseminated malignant melanoma. Proc. ASCO C-135 (1977)
Hilal, E. Y. et al., Surgical adjuvant therapy of malignant melanoma with C. parvum. Proc. ASCO C-229 (1977)
Hill, G. J. et al., DTIC therapy for melanoma: correlation of toxicity with response and longevity in 742 patients. Proc. ASCO C-30 (1976)
Hill, G. J. et al., DTIC-melanoma adjuvant study. Final report. Proc. ASCO C—11 (1978)
Herrmann, W. P. et al., Rückbildung von Melanommetastasen nach Injektion von Freund’schem Adjuvans. Hautarzt 21, 181–183 (1970)
Hunter-Craig, I. et al., Use of vaccinia virus in the treatment of metastatic malignant melanoma. Brit. med. J. 1, 512–515 (1970)
Ishmael, D. R. et al., Results of treatment of surgically resected melanoma with immunotherapeutic agents BCG and C. parvum. Proc. ASCO C-309 (1977)
Jungi, W. F., BCG in der Krebstherapie — Wunschtraum oder Therapie der Zukunft? Schw. med. Wschr. 106, 1389–1391 (1976)
Jungi, W. F. et al., unveröffentlichte Ergebnisse
Khan, A. et al., Immunotherapy of metastatic melanoma with transfer factor, Proc. ASCO C-154 (1976)
Kleeberg, U. R., Die Behandlung des Melanoms. Dtsch. med. Wschr. 101, 904–908 (1976)
Krown, S. E. et al., Intralesional injection of MER in cutaneous malignant melanoma. Proc. ASCO C-300 (1977)
Lichtenfeld, J. L., Current concepts in the management of malignant melanoma. Amer. J. Med. Sci. 272, 184–195 (1976)
Luce, J. K., Chemotherapy of melanoma. Semin. Oncol. 2, 179–185 (1975)
Malek-Mansour, S., Immunotherapy of melanoma with DNCB. In „Adjuvant therapy of Cancer”, Amsterdam: Elsevier/North Holland 1976, p. 447–454
McIllmurray, M. B. et al., Controlled trial of active immunotherapy in management of stage II B malignant melanoma. Brit. med. J. 1, 540–542 (1977)
McMurtrey, M. J. et al., Adjuvant chemoimmunotherapy for stage III malignant melanoma. Proc. ASCO C-168 (1977)
McPherson, T. A. et al.,: a pilot study of adjuvant chemoimmuno-therapy. In „Adjuvant therapy of cancer”, Amsterdam: Elsevier/North Holland 1976, p. 439–446
Mitchell, M. S. et al., Effect of chemotherapy and immunotherapy on tumor-specific immunity in melanoma. J. Clin. Invest. 59, 1017–1026 (1977)
Minton, J. P., Mumps virus and BCGvaccine in metastatic melanoma. Arch. surg. 106, 503–506 (1973)
Morton, D. L. et al., Adjuvant therapy in melanoma and sarcomas. In „Adjuvant therapy of cancer”, Elsevier/North Holland, Amsterdam 1976, p. 391–397
Morton, D. L. et al., Present status of BCG immunotherapy of malignant melanoma. Cancer Immunol. Immunother. 1, 93–98 (1976)
Morton, D. L., Cancer Immunotherapy. An overview. Semin. Oncol. 1, 297 (1974)
Nathanson, L., Regression of intradermal malignant melanoma after intralesional injection of BCG. Cancer Chemother. Rep. Vol. 1, 56, 659–665 (1972)
Nathanson, L. et al., A comparative study of 2 methods of administration of BCG in malignant melanoma. Proc. ASCO C-14 (1976)
Obrecht, J. P. et al., persönliche Mitteilung
Patt, Y. et al., Prognostic significance of initial immunological evaluation in stage 3B melanoma treated with thymosin, BCG and DTIC. Proc. ASCO C-72 (1977)
Perry, H. O., Winkelmann R. K., The experimental use of phenylalanine-mustard in the treatment of malignant melanomas. Acta derm.-venereol. 49, 564–568 (1969)
Presant, C. A., Therapy of metastatic malignant melanoma with cyclophosphamide plus DTIC with or without C. parvum. Proc. ASCO C-68 (1977)
Pritchard, K. I., The use of oral BCG in the treatment of metastatic malignant melanoma. Med. Ped. Oncol. 2, 173–181 (1976)
Richman, S. P. et al., Epilesional scarification. J. amer. med. ass. 234, 1233–1235 (1975)
Saal, J. G. et al., Regional BCG-therapy of malignant melanoma: in vitro monitoring of spontaneous cytolytic activity of circulating lymphocytes. Cancer Immunol. Immunother. 2, (1977)
Salmon, S. E., Immunotherapy of cancer: present status of trials in man. Cancer Res. 37, 1245–1248 (1977)
Sears, H., Rosenberg S. A., Immune depression with BCG septicemia. Proc. ASCO C-245 (1977)
Seigler, H. F. et al., Non-specific and specific immunotherapy in patients with melanoma. Surgery 72, 162–174 (1975)
Serrou, B. et al., Improved clinical results of malignant melanoma with complementary chemo-immunotherapy. Proc. ASCO C-349 (1977)
Tritsch, H., Onkolyse bei Melanom-Lymphknotenmetastasen. Dtsch. med. Wschr. 95, 2432–2433 (1970)
Wright, P. W. et al., Immunotherapy with „unblocking” plasma in malignant melanoma: in vivo and in vitro correlates. Proc. ASCO, C-136 (1977)
Author information
Authors and Affiliations
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 1978 Springer-Verlag Berlin Heidelberg
About this paper
Cite this paper
Jungi, W.F. (1978). Adjuvante Chemo-Immunotherapie beim malignen Melanom. In: Huber, H., Senn, H., Falkensammer, M. (eds) Adjuvante zytostatische Chemotherapie. Hämatologie und Bluttransfusion, vol 22. Springer, Berlin, Heidelberg. https://doi.org/10.1007/978-3-642-67111-1_18
Download citation
DOI: https://doi.org/10.1007/978-3-642-67111-1_18
Publisher Name: Springer, Berlin, Heidelberg
Print ISBN: 978-3-540-09069-4
Online ISBN: 978-3-642-67111-1
eBook Packages: Springer Book Archive